Tuesday, April 16, 2019 Daily Archives

Shareholders’ nod puts $74bn BMS Celgene merger back on track

by

Over 75% of Bristol-Myers Squibb shareholders voted in favor of the proposed megamerger with Celgene despite warnings from certain investor groups. In January, Big Pharma firm Bristol-Myers Squibb (BMS) announced its intentions to get bigger through the acquisition of its immune-oncology partner Celgene. The $74 billion (€65 billion), if it goes through, will be the largest ever merger in the biopharma space and create what Bristol-Myers Squibb CEO Giovanni Caforio described as “the number one oncology franchise.†The deal is on track…

April 16, 2019

Enesi and BARDA partner to develop solid dose flu vaccine

by

The US Biomedical Advanced Research and Development Authority (BARDA) will use Enesi Pharma’s ImplaVax device and formulation technology to develop subcutaneous vaccines against influenza. The public-private collaboration, financials of which have not been divulged, will form part of BARDA’s Division of Research, Innovation, and Ventures (DRIVe) innovative health security technologies portfolio, and looks to provide a cost-effective alternative to traditional vaccines to help improve vaccination uptake. The aim is to help healthcare providers or individuals administer influenza vaccines through the…

April 16, 2019